Staff members (REF1a/c)
1 - Clinical Medicine
University of Leeds
- D - Cardiovascular
- B - Genes and Development
- A - Cancer
- D - Cardiovascular
- C - Musculoskeletal
- A - Cancer
- D - Cardiovascular
- C - Musculoskeletal
Bennett is a full time military and Honorary NHS Consultant Rheumatologist within Guys and St Thomas’ Hospitals London and holds an Honorary Senior Lecture post with the Leeds Institute of Rheumatic and Musculoskeletal Medicine at the University of Leeds. He has research interests in the clinical aspects of rheumatology, rehabilitation and sports medicine, in particular in the fields of early diagnosis and prognosis of spondyloarthritis and trauma and rehabilitation outcomes. He has on going collaborations and current research studies with University of Leeds UoA1 returnees (McGonagle, Emery, Marzo-Ortega, Coates and Conaghan), with respect to evaluating MRI in SpA and early OA. He has published 16 papers in the last 5 years, with 15 published with the aforementioned UoA1 returnees.
- A - Cancer
- D - Cardiovascular
Blackman has an honorary contract with the University of Leeds. He specialises in interventional cardiology. He is leading the Leeds Programme in valvular intervention including percutaneous aortic valve replacement. He interacts on a daily basis with clinical academics in particular our cardiac MRI researchers and is a co-author on Greenwood’s returned output #2 “Serial change in health-related quality of life over 1 year after transcatheter aortic valve implantation: predictors of health outcomes”. He is part funded by local CLRN funding to deliver patient orientated research, as stated in his job plan.
- B - Genes and Development
- A - Cancer
Bowen is an NHS consultant haematologist and Honorary Professor of Myeloid Leukaemia Studies at the University of Leeds with a research interest in the myelodysplastic syndromes, acute myeloid leukaemia and myeloproliferative disorders.
Throughout the REF period Bowen has worked in the haematologic oncology team with University of Leeds haematology colleagues returned in REF UOA1 (Hillmen, Gordon Cook), and with NHS colleagues (including Rawstron; Category C).
Bowen has published 24 papers listed on PubMed in the last 5 years, of which 3 were co-authored with University of Leeds UOA1 returnees (Errington-Mais, Hillmen, Melcher, Selby, Vile; all Category A).
Bowen has made important contributions to the patients with treatment of myeloid malignancies.
- D - Cardiovascular
- C - Musculoskeletal
- B - Genes and Development
- D - Cardiovascular
- A - Cancer
- C - Musculoskeletal
- C - Musculoskeletal
- A - Cancer
- A - Cancer
- D - Cardiovascular
- C - Musculoskeletal
Dr Dass is an Honorary Senior Lecturer at the University of Leeds working closely with UoA1 returnees in the Leeds Institute of Rheumatic and Musculoskeletal Medicine (Emery, Buch, Morgan, Vital). He was critical in establishing a clinical research programme investigating rituximab therapy in a broad range of musculoskeletal diseases and Leeds is now internationally renowned for work in this area. This cohort was included in the successful MRC Stratified Medicine award to the MATURA Consortium (Morgan Co-I). In addition, he was PI for the TERRA study (industry sponsored multicentre trial of revamilast in rheumatoid arthritis). Currently sub-investigator on TRACTISS, DCVAS and GIACTA studies (PIs Emery and Morgan). Lead representative for this Unit in the BRILL network (national network for research into interstitial lung disease in rheumatic conditions). He has published 7 papers in the last 5 years, with all 7 co-authored with UoA1 returnees (Emery, Buch, Vital).
- C - Musculoskeletal
- A - Cancer
Dodwell is an honorary senior lecturer at the University and a clinical oncologist with a research interest in breast cancer.
Throughout the REF period Dodwell has worked in the breast cancer team with senior University of Leeds colleagues returned in REF UOA1 who are fellow clinicians (Twelves, Velikova, Perren), pathologists (Hanby) and laboratory scientists (Speirs), and with NHS colleagues (including Horgan; Category C).
Over the last 5 years Dodwell has been Principal Investigator on 3 breast cancer clinical trials (with Perren, Twelves and Velikova as Co-Investigators; all UOA1 Category A), and Co-Investigator on numerous others.
Dodwell has a distinguished record in clinical trials, with 40 peer-reviewed papers in the last 5 years, of which 8 were co-authored with University of Leeds UOA1 returnees (Hanby, Speirs, Perren, Velikova; all Category A).
Dodwell has made important contributions to clinical trials that have informed changes in the treatment of women with breast cancer.
- A - Cancer
- A - Cancer
- C - Musculoskeletal
- A - Cancer
- B - Genes and Development
Finan is an NHS consultant surgeon and Honorary Professor at the University with a research interest in colorectal cancer surgery.
Throughout the REF period Finan has worked in the colorectal cancer team with University of Leeds colleagues returned in REF UOA1 who are fellow clinicians (Seymour, Sebag-Montefiore) and pathologists (Quirke, West).
Finan has published 24 peer-reviewed papers in the last 5 years, of which 14 were co-authored with University of Leeds UOA1 returnees (Sebag-Montefiore, Quirke, Seymour, West; all Category A).
Finan has made important contributions to the treatment of patients with colorectal cancer, and in particular on long-term clinical outcomes.
- C - Musculoskeletal
- A - Cancer
- C - Musculoskeletal
Grainger is an Honorary Clinical Associate Professor at the University of Leeds within the Leeds Institute of Rheumatic and Musculoskeletal Medicine. He is a foundation member of the NIHR funded Leeds Musculoskeletal Biomedical Research Unit. Working with the musculoskeletal team returned in UoA1 (Emery, Conaghan, Wakefield, Freeston, Helliwell, McGonagle, O’Connor), he has been involved in developing novel imaging biomarkers, which have changed how RA is assessed. In collaboration with the University of Boston, he developed a novel scoring system for assessing osteoarthritis on MRI (Boston Leeds OA knee score) that is now used in clinical trials. He has published 22 peer reviewed publications in the last 5 years, 17 with the aforementioned UoA1 returnees, with an H-index of 17.
- D - Cardiovascular
- D - Cardiovascular
- A - Cancer
- A - Cancer
- C - Musculoskeletal
- A - Cancer
- A - Cancer
- B - Genes and Development
- B - Genes and Development
Horgan is an Honorary Clinical Associate Professor in Breast and Sarcoma Surgery in the University and a senior consultant breast surgeon with a research interest in breast cancer.
Throughout the REF period Horgan has worked closely with non-surgical oncologists in the breast team who are returned in UOA1 (Hanby, Perren, Speirs, Twelves, Velikova; all Category A), laboratory researchers (Hughes; Category A) and NHS colleagues (including Dodwell; Category C).
Horgan has published 36 papers listed on PubMed in the last 5 years, all directly or indirectly relating to cancer research, including 11 co-authored with UOA1 returnees (Hanby, Hughes, Perren, Speirs, Velikova; all Category A)
Horgan has made important contributions to clinical and laboratory studies in breast cancer.
- A - Cancer
- B - Genes and Development
- A - Cancer
- A - Cancer
- B - Genes and Development
- C - Musculoskeletal
- D - Cardiovascular
- A - Cancer